Michael Mollerus

Davis Polk advised BRP Group, Inc. on its acquisition of all of the outstanding equity interests of Armfield, Harrison & Thomas, Inc. Financial terms of the transaction were not…

Davis Polk is advising IHS Markit on its all-stock merger with S&P Global that values IHS Markit at an enterprise value of $44 billion. Under the terms of the merger agreement, each…

Davis Polk is advising Bertelsmann on the $2.175 billion acquisition by its global trade book publishing group, Penguin Random House, of Simon & Schuster from ViacomCBS. The transaction…

Davis Polk advised the representatives of the underwriters in connection with the $112 million public offering of 2,500,000 shares of common stock of Stoke Therapeutics, Inc., which…

We are advising VF on its acquisition

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $728 million secondary offering of 17,343,037 of its Class A ordinary shares by certain selling…

Davis Polk is advising Morgan Stanley on its $7 billion acquisition of Eaton Vance Corp. The acquisition is subject to customary closing conditions and is expected to close in the second…

Davis Polk advised Gilead Sciences, Inc. in connection with an SEC-registered offering of $7.25 billion aggregate principal amount of senior notes, consisting of (i) $500 million aggregate…

Davis Polk advised American Well Corporation (“Amwell”) in connection with its initial public offering of 47,405,555 shares of Class A common stock for approximately $853 million in total…

Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion,…